Spartan Fund Management Inc. acquired a new position in shares of DA32 Life Science Tech Acquisition Corp. (NASDAQ:DALS – Get Rating) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,824 shares of the company's stock, valued at approximately $181,000. Spartan Fund Management Inc. owned about 0.06% of DA32 Life Science Tech Acquisition at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Exos Asset Management LLC raised its holdings in DA32 Life Science Tech Acquisition by 4.6% during the first quarter. Exos Asset Management LLC now owns 76,951 shares of the company's stock worth $748,000 after buying an additional 3,402 shares during the last quarter. Ursa Fund Management LLC acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $243,000. Piper Sandler & CO. acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $244,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $486,000. Finally, Fir Tree Capital Management LP acquired a new position in DA32 Life Science Tech Acquisition during the first quarter worth $758,000. Institutional investors and hedge funds own 60.43% of the company's stock.

DA32 Life Science Tech Acquisition Stock Performance

DALS opened at $9.74 on Friday. The company's fifty day moving average price is $9.72 and its two-hundred day moving average price is $9.71. DA32 Life Science Tech Acquisition Corp. has a 1-year low of $9.58 and a 1-year high of $10.26.

About DA32 Life Science Tech Acquisition

DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.

See Also

• Get a free copy of the StockNews.com research report on DA32 Life Science Tech Acquisition (DALS)
• Is There a Cure for What is Ailing Teladoc Stock?
• No One Told These 3 Stocks It's a Down Week
• Why Medical Products Maker Repligen May Be A Potential Buy
• At 10%, Is Arbor Realty Trust Dividend Worth It?
• Investors Should Tune Into RF Industries

Receive News & Ratings for DA32 Life Science Tech Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DA32 Life Science Tech Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.